Astellas Pharma Inc. and Pfizer Inc. announced that XTANDI® plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
